Letter to the FDA Urging Postponement of the Approval Decision Regarding Lecanemab for Treatment of Alzheimer’s Disease

View as PDF

View press release

In a letter to the Food and Drug Administration (FDA), Public Citizen urged the FDA to postpone the approval decision regarding lecanemab for treatment of Alzheimer’s disease until the agency convenes an advisory committee to consider the new drug application for the drug.